Patents by Inventor Eric M. MUCKER

Eric M. MUCKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines
    Publication number: 20230390389
    Abstract: A nucleic acid vaccine composition comprising one or more of a plasmid-based nucleic acid vaccine and immunotherapy, as well as a lipid formulation, is provided. In addition, the present invention provides a method of enhancing the potency of plasmid-based DNA vaccines and immunotherapies, by formulating a vaccine and/or immunotherapy in a lipid formulation, which is stable when refrigerated or stored frozen, is then delivered to a vaccinee by either needle/syringe, jet injection, or microneedles. The lipid formulation of the present invention comprises one or more lipid excipients selected from 1,2-Distearoyl-sn-glycero-3-phosphocholine, Cholest-5-en-3?-ol, 1,2-Dimyristoyl-rac-glycero-3-methylpolyoxyethlene, and or more symmetric ionizable cationic lipids. The present invention increases vaccine potency dramatically.
    Type: Application
    Filed: August 18, 2023
    Publication date: December 7, 2023
    Applicants: The Government of the United States, as Represented by the Secretary of the Army, Arcturus Therapeutics, Inc.
    Inventors: Jay W. HOOPER, Eric M. MUCKER, Padmanabh CHIVUKULA
  • NUCLEIC ACID VACCINE COMPOSITION COMPRISING A LIPID FORMULATION, AND METHOD OF INCREASING THE POTENCY OF NUCLEIC ACID VACCINES
    Publication number: 20200046830
    Abstract: A nucleic acid vaccine composition comprising one or more of a plasmid-based nucleic acid vaccine and immunotherapy, as well as a lipid formulation, is provided. In addition, the present invention provides a method of enhancing the potency of plasmid-based DNA vaccines and immunotherapies, by formulating a vaccine and/or immunotherapy in a lipid formulation, which is stable when refrigerated or stored frozen, is then delivered to a vaccinee by either needle/syringe, jet injection, or microneedles. The lipid formulation of the present invention comprises one or more lipid excipients selected from 1,2-Distearoyl-sn-glycero-3-phosphocholine, Cholest-5-en-3?-ol, 1,2-Dimyristoyl-rac-glycero-3-methylpolyoxyethlene, and or more symmetric ionizable cationic lipids. The present invention increases vaccine potency dramatically.
    Type: Application
    Filed: March 30, 2018
    Publication date: February 13, 2020
    Inventors: Jay W. HOOPER, Eric M. MUCKER, Padmanabh CHIVUKULA